Brian L Henry1, Beth Gabris1, Qiao Li1, Brian Martin2, Marianna Giannini1, Ashish Parikh2, Divyang Patel1, Jamie Haney2, David S Schwartzman1, Sanjeev G Shroff2, Guy Salama3. 1. University of Pittsburgh School of Medicine, Heart and Vascular Institute, Pittsburgh, Pennsylvania. 2. University of Pittsburgh Department of Bioengineering, and the McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania. 3. University of Pittsburgh School of Medicine, Heart and Vascular Institute, Pittsburgh, Pennsylvania,; University of Pittsburgh Department of Bioengineering, and the McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania. Electronic address: gsalama@pitt.edu.
Abstract
BACKGROUND: Atrial fibrillation (AF) contributes significantly to morbidity and mortality in elderly patients and has been correlated with enhanced age-dependent atrial fibrosis. Reversal of atrial fibrosis has been proposed as therapeutic strategy to suppress AF. OBJECTIVE: To test the ability of relaxin to reverse age-dependent atrial fibrosis and suppress AF. METHODS: Aged F-344 rats (24 months old) were treated with subcutaneous infusion of vehicle or relaxin (0.4 mg/kg/day) for 2 weeks. Rat hearts were excised, perfused on a Langendorff apparatus, and stained with voltage and Ca(2+) indicator dyes. Optical mapping and programmed electrical stimulation was used to test arrhythmia vulnerability and changes in electrophysiological characteristics. Changes in protein expression and Na(+) current density (INa) were measured by tissue immunofluorescence and whole-cell patch clamp technique. RESULTS: In aged rats, sustained AF was readily induced with a premature pulse (n = 7/8) and relaxin treatment suppressed sustained AF by a premature impulse or burst pacing (n = 1/6) (P < .01). Relaxin significantly increased atrial action potential conduction velocity and decreased atrial fibrosis. Relaxin treatment increased Nav1.5 expression (n = 6; 36% ± 10%) and decreased total collagen and collagen I (n = 5-6; 55%-66% ± 15%) in aged atria (P < .05) and decreased collagen I and III and TGF-β1 mRNA (P < .05). Voltage-clamp experiments demonstrated that relaxin treatment (100 nM for 2 days) increased atrial INa by 46% ± 4% (n = 12-13/group, P < .02). CONCLUSION: Relaxin suppresses AF through an increase in atrial conduction velocity by decreasing atrial fibrosis and increasing INa. These data provide compelling evidence that relaxin may serve as an effective therapy to manage AF in geriatric patients by reversing fibrosis and modulating cardiac ionic currents.
BACKGROUND:Atrial fibrillation (AF) contributes significantly to morbidity and mortality in elderly patients and has been correlated with enhanced age-dependent atrial fibrosis. Reversal of atrial fibrosis has been proposed as therapeutic strategy to suppress AF. OBJECTIVE: To test the ability of relaxin to reverse age-dependent atrial fibrosis and suppress AF. METHODS: Aged F-344 rats (24 months old) were treated with subcutaneous infusion of vehicle or relaxin (0.4 mg/kg/day) for 2 weeks. Rat hearts were excised, perfused on a Langendorff apparatus, and stained with voltage and Ca(2+) indicator dyes. Optical mapping and programmed electrical stimulation was used to test arrhythmia vulnerability and changes in electrophysiological characteristics. Changes in protein expression and Na(+) current density (INa) were measured by tissue immunofluorescence and whole-cell patch clamp technique. RESULTS: In aged rats, sustained AF was readily induced with a premature pulse (n = 7/8) and relaxin treatment suppressed sustained AF by a premature impulse or burst pacing (n = 1/6) (P < .01). Relaxin significantly increased atrial action potential conduction velocity and decreased atrial fibrosis. Relaxin treatment increased Nav1.5 expression (n = 6; 36% ± 10%) and decreased total collagen and collagen I (n = 5-6; 55%-66% ± 15%) in aged atria (P < .05) and decreased collagen I and III and TGF-β1 mRNA (P < .05). Voltage-clamp experiments demonstrated that relaxin treatment (100 nM for 2 days) increased atrial INa by 46% ± 4% (n = 12-13/group, P < .02). CONCLUSION:Relaxin suppresses AF through an increase in atrial conduction velocity by decreasing atrial fibrosis and increasing INa. These data provide compelling evidence that relaxin may serve as an effective therapy to manage AF in geriatric patients by reversing fibrosis and modulating cardiac ionic currents.
Authors: Edna D Lekgabe; Helen Kiriazis; Chongxin Zhao; Qi Xu; Xiao Lei Moore; Yidan Su; Ross A D Bathgate; Xiao-Jun Du; Chrishan S Samuel Journal: Hypertension Date: 2005-06-20 Impact factor: 10.190
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Y Y Li; Y Q Feng; T Kadokami; C F McTiernan; R Draviam; S C Watkins; A M Feldman Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205
Authors: Norishige Morita; Jong-Hwan Lee; Aneesh Bapat; Michael C Fishbein; William J Mandel; Peng-Sheng Chen; James N Weiss; Hrayr S Karagueuzian Journal: Am J Physiol Heart Circ Physiol Date: 2011-04-08 Impact factor: 4.733
Authors: Sander Verheule; Els Tuyls; Ali Gharaviri; Sarah Hulsmans; Arne van Hunnik; Marion Kuiper; Jan Serroyen; Stef Zeemering; Nico H L Kuijpers; Ulrich Schotten Journal: Circ Arrhythm Electrophysiol Date: 2013-02-06
Authors: Yangyang Bao; B Cicero Willis; Chad R Frasier; Luis F Lopez-Santiago; Xianming Lin; Roberto Ramos-Mondragón; David S Auerbach; Chunling Chen; Zhenxun Wang; Justus Anumonwo; Héctor H Valdivia; Mario Delmar; José Jalife; Lori L Isom Journal: Circ Arrhythm Electrophysiol Date: 2016-12
Authors: A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago Journal: Endocrine Date: 2018-02-06 Impact factor: 3.633
Authors: Brian Martin; Rebecca R Vanderpool; Brian L Henry; Joshua B Palma; Beth Gabris; Yen-Chun Lai; Jian Hu; Stevan P Tofovic; Rajiv P Reddy; Ana L Mora; Mark T Gladwin; Guillermo Romero; Guy Salama Journal: Front Cardiovasc Med Date: 2021-07-06
Authors: Christian Veltmann; Hector Barajas-Martinez; Christian Wolpert; Martin Borggrefe; Rainer Schimpf; Ryan Pfeiffer; Gabriel Cáceres; Elena Burashnikov; Charles Antzelevitch; Dan Hu Journal: J Am Heart Assoc Date: 2016-07-05 Impact factor: 5.501
Authors: Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago Journal: Front Physiol Date: 2017-08-18 Impact factor: 4.566